Reviewing Concert Pharmaceuticals Inc. (CNCE)’s and Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)’s results

Concert Pharmaceuticals Inc. (NASDAQ:CNCE) and Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) are two firms in the Biotechnology that compete against each other. Below is a comparison of their analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Concert Pharmaceuticals Inc. 7 0.00 19.14M -3.13 0.00
Vanda Pharmaceuticals Inc. 15 0.10 40.60M 0.39 31.68

Table 1 highlights Concert Pharmaceuticals Inc. and Vanda Pharmaceuticals Inc.’s top-line revenue, earnings per share (EPS) and valuation.


Table 2 shows the return on assets, net margins and return on equity of the two firms.

Net Margins Return on Equity Return on Assets
Concert Pharmaceuticals Inc. 284,398,216.94% -41.7% -36.5%
Vanda Pharmaceuticals Inc. 270,306,258.32% 8.1% 6.6%

Volatility & Risk

Concert Pharmaceuticals Inc. is 17.00% less volatile than S&P 500 because the company has a beta of 0.83. Vanda Pharmaceuticals Inc.’s 65.00% less volatile than S&P 500 which is a result of the 0.35 beta.


20.4 and 20.4 are the respective Current Ratio and a Quick Ratio of Concert Pharmaceuticals Inc. Its rival Vanda Pharmaceuticals Inc.’s Current and Quick Ratios are 5.2 and 5.2 respectively. Concert Pharmaceuticals Inc. has a better chance of clearing its pay short and long-term debts than Vanda Pharmaceuticals Inc.

Analyst Ratings

The Ratings and Recommendations for Concert Pharmaceuticals Inc. and Vanda Pharmaceuticals Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Concert Pharmaceuticals Inc. 0 0 3 3.00
Vanda Pharmaceuticals Inc. 0 1 1 2.50

The upside potential is 186.89% for Concert Pharmaceuticals Inc. with average target price of $21. Vanda Pharmaceuticals Inc. on the other hand boasts of a $18 average target price and a 3.03% potential upside. The results from earlier shows that analysts view suggest that Concert Pharmaceuticals Inc. seems more appealing than Vanda Pharmaceuticals Inc.

Insider and Institutional Ownership

Institutional investors owned 81.8% of Concert Pharmaceuticals Inc. shares and 0% of Vanda Pharmaceuticals Inc. shares. Concert Pharmaceuticals Inc.’s share owned by insiders are 3.2%. Competitively, Vanda Pharmaceuticals Inc. has 3.6% of it’s share owned by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Concert Pharmaceuticals Inc. -4.55% -16.72% -1.28% -29.5% -38.24% -19.84%
Vanda Pharmaceuticals Inc. -5.61% -10.43% -22.19% -55.85% -37.59% -52.35%

For the past year Concert Pharmaceuticals Inc. has stronger performance than Vanda Pharmaceuticals Inc.


Vanda Pharmaceuticals Inc. beats Concert Pharmaceuticals Inc. on 7 of the 13 factors.

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. It discovers and develops novel small molecule drugs for use in the treatment of various pulmonary diseases, including cystic fibrosis, autoimmune and inflammatory diseases, and central nervous systems disorders. The companyÂ’s clinical-stage product candidates include AVP-786, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with AlzheimerÂ’s disease; and CTP-656, which is in Phase 2 clinical trials to treat cystic fibrosis. It product candidates that have completed Phase 1 clinical trials comprise CTP-730 for use in the treatment of inflammation or cancer; JZP-386 for use in the treatment of excessive daytime sleepiness and cataplexy; and CTP-543 for use in the treatment of alopecia areata. The company has strategic collaborations with Celgene Pharmaceuticals, Inc.; Celgene International Sarl; Celgene Corporation; Avanir Pharmaceuticals, Inc.; and Jazz Pharmaceuticals, Inc. Concert Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The companyÂ’s marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorder; and Fanapt (iloperidone), a product for the treatment of schizophrenia. Its clinical development products include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; Trichostatin A, a small molecule histone deacetylase inhibitor, which is in development for the treatment of hematologic malignancies; and AQW051, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. The company markets its products in the United States, Canada, Europe Union, Israel, and Mexico. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.